NetworkNewsBreaks

ThursdayMar 05, 2020 12:31 pm

NetworkNewsBreaks – Arcturus Therapeutics Holdings, Inc. (NASDAQ: ARCT) Featured in ROTH Equity Research Report

Arcturus Therapeutics Holdings, Inc. (NASDAQ: ARCT) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “With global public health concerns around continued COVID-19 infection, ARCT announced a partnership (funded up to $10M) early this morning with Duke-NUS (Singapore) to utilize its STARR technology for vaccine development. With STARR incorporating the essential elements of LUNAR mRNA design, we see a potential dataset in COVID-19 as an expedited shot on goal for validation of its mRNA platform.” To request access to the full report, visit http://nnw.fm/DXCr3 About Arcturus Therapeutics Holdings, Inc. Founded in 2013…

Continue Reading

ThursdayMar 05, 2020 12:23 pm

NetworkNewsBreaks – Heritage-Crystal Clean Inc. (NASDAQ: HCCI) Featured in ROTH Equity Research Report

Heritage-Crystal Clean Inc. (NASDAQ: HCCI) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Results outperformed on the top line and met EBITDA expectations. ES growth was aided by a field service project, which also impacts 1Q 20. Field service work aside, branch activity remains robust with projected organic growth of 7-9%. Oil revenue was in line and re-refinery operations continue to operate well with plant capacity expanding. Margins were impacted by headwinds in ES, which should abate by 2H 2020. ES has a runway of growth; Oil continues to improve –…

Continue Reading

ThursdayMar 05, 2020 12:21 pm

NetworkNewsBreaks – Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) Enters Cooperation Agreement with Chinese Metals Supplier

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) today announced its entry into a non-binding cooperation agreement with Hunan Shijiyintian New Material Co., Ltd, an 100% wholly owned subsidiary of Hunan Jinxin New Material Co., Ltd. ("Hunan Jinxin"). Bolt Metals and Hunan Jinxin will immediately commence negotiations with the intention of entering into one or more definitive binding agreements definitive agreement, subject to further due diligence to be completed between the parties. According to the update, it is anticipated that there will be two primary components of a definitive agreement, including a preliminary offtake and investment. “While recent market…

Continue Reading

ThursdayMar 05, 2020 12:16 pm

NetworkNewsBreaks – Vectrus Inc. (NYSE: VEC) Featured in Noble Capital Markets Research Update

Vectrus Inc. (NYSE: VEC) was featured in a recent equity research update published by Noble Capital Markets. The report reads, “Strong 4Q19 and FY2019. 4Q19 revenue grew 11% to $365.3 million, adjusted EBITDA rose 29% to $18 million and adjusted diluted EPS was $0.93 compared to $0.73 in 4Q18. Full year revenue was up 8% to $1.38 billion, adjusted EBITDA rose 15% to $61.4 million, and adjusted diluted EPS was $3.21 compared to $3.04 in 2018.” To view the update and gain access to the full report, visit http://nnw.fm/k0POY About Vectrus Inc. Vectrus is a leading provider of global service solutions with…

Continue Reading

ThursdayMar 05, 2020 12:09 pm

NetworkNewsBreaks – MCTC Holdings, Inc. (MCTC) Enters Sales and Distribution Agreement with Sinister CBD LLC for Hemp You Can Feel(TM) Coffee Product Line

MCTC Holdings (OTC: MCTC), a cannabinoid and hemp extract science forward company developing infusion and delivery technologies, today announced its receipt of an initial order from Sinister CBD, LLC for sales and distribution of its Hemp You Can Feel(TM) Coffee product line. Hemp You Can Feel(TM), MCTC’s new product line based on its patent-pending infusion technologies, is the industry's first 100% natural hemp extract and CBD coffee to be shipped in 100% compostable single-serving coffee pods. Under the agreement, MCTC will private label its coffee products under the Sinister CBD brand name and other brands to be included in subsequent…

Continue Reading

ThursdayMar 05, 2020 12:01 pm

NetworkNewsBreaks – aTyr Pharma Inc. (NASDAQ: LIFE) Featured in ROTH Equity Research Report

aTyr Pharma Inc.  (NASDAQ: LIFE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are initiating coverage of aTyr with a Buy rating and $15 PT. Our investment thesis is based on 1) strong scientific data for aTYR’s lead candidate, ATYR1923, a tRNA synthetase-derived drug for Pulmonary Sarcoidosis an interstitial lung disease (ILD) for which efficacy data is expected during 3Q20, 2) '1923's potential to capture share in the larger ILD market, and 3) collaborations with CSL-Behring (CSLLY-NC) and Kyorin (4569:TYO-NC) that provide further platform validation and non-dilutive capital.” To request…

Continue Reading

ThursdayMar 05, 2020 11:54 am

NetworkNewsBreaks – Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report

Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are including IQVIA scripts for Gvoke and glucagon below for the week ended 2/21/2020. Gvoke TRx was +24.6% to 294 from 236 the prior week; Gvoke NRx was +26.8% to 284 from 224 the prior week. Total Glucagon TRx was 12,004, +14.0% y/y; total Glucagon NRx was +14.1% y/y to 9,509.” To request access to the full report, visit http://nnw.fm/SaZ9d About Xeris Pharmaceuticals, Inc. Xeris is a specialty pharmaceutical company delivering innovative solutions to simplify the experience…

Continue Reading

ThursdayMar 05, 2020 11:47 am

NetworkNewsBreaks – Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Featured in Mizuho Securities Research Report

Concert Pharmaceuticals, Inc.  (NASDAQ: CNCE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Concert reported 4Q19/FY19 results yesterday. 4Q19 EPS was $(0.86) compared to FactSet consensus of $(0.79) while FY19 EPS was $(3.29) vs. consensus of $(3.22). We do not see earnings as the most important value driver for pre-commercial stage biotechs. Importantly, the company continues to make progress on the clinical development front with CTP-543, and CTP-692 - two wholly-owned assets. We continue to expect that the Phase 2 readouts from CTP-692 in schizophrenia expected by YE2020 could be an…

Continue Reading

ThursdayMar 05, 2020 11:39 am

NetworkNewsBreaks – Forty Seven, Inc. (NASDAQ: FTSV) Featured in Mizuho Securities Research Report

Forty Seven, Inc. (NASDAQ: FTSV) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “GILD to acquire FTSV in an all cash deal for $95.50 per share, valuing FTSV at ~$4.9 bln. The deal is expected to close 2Q20, and is subject to regulatory approvals and other customary closing conditions. We have previously written about the possibility of an acquisition or partnership in a previous note.” To request access to the full report, visit http://nnw.fm/SaZ9d About Forty Seven, Inc. Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer…

Continue Reading

ThursdayMar 05, 2020 11:26 am

NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Featured in Mizuho Securities Research Report

Zogenix, Inc. (NASDAQ: ZGNX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Zogenix reported earnings yesterday. 4Q19 EPS was $(1.26) vs. FactSet consensus of $(1.04) and FY19 EPS was $(9.74) vs. consensus of $(9.54). We do not see earnings as the most important value driver for ZGNX at this stage. Importantly, we remain confident in the potential FDA approval of FINTEPLA for the treatment of Dravet syndrome (PDUFA: 06/25/20). On yesterday's call, management highlighted two-year interim data showing long-term reductions in seizure frequency, supporting our view that FINTEPLA may be differentiated…

Continue Reading